{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T19:43:27Z","timestamp":1786563807832,"version":"build-2736575974"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1038\/ajg.2010.21","type":"journal-article","created":{"date-parts":[[2010,2,16]],"date-time":"2010-02-16T10:54:15Z","timestamp":1266317655000},"page":"1620-1626","source":"Crossref","is-referenced-by-count":53,"title":["Changes in Liver Biochemistry During Methotrexate Use for Inflammatory Bowel Disease"],"prefix":"10.14309","volume":"105","author":[{"given":"Marc R","family":"Fournier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald Y","family":"Minuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles N","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-27-20210210","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.3748\/wjg.v12.i23.3657","article-title":"Pharmacogenetics in inflammatory bowel disease.","volume":"12","author":"Pierik","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R2-27-20210210","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7326\/0003-4819-110-5-353","article-title":"Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.","volume":"110","author":"Kozarek","year":"1989","journal-title":"Ann Intern Med"},{"key":"R3-27-20210210","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohns disease.","volume":"342","author":"Feagan","year":"2000","journal-title":"N Engl J Med"},{"key":"R4-27-20210210","first-page":"2203","article-title":"Methotrexate in chronic active Crohns disease: a double-blinded, randomized, Israeli multicenter trial.","volume":"92","author":"Oren","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"R5-27-20210210","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1046\/j.1365-2036.1999.00667.x","article-title":"A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohns disease and ulcerative colitis.","volume":"13","author":"Egan","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-27-20210210","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1572-0241.2003.07305.x","article-title":"Low dose methotrexate in inflammatory bowel disease: current status and future directions.","volume":"98","author":"Schroser","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R7-27-20210210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4065\/71.1.69","article-title":"Methotrexate for inflammatory bowel disease: pharmacology and preliminary results.","volume":"71","author":"Egan","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"R8-27-20210210","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.biopha.2006.09.007","article-title":"The use of low dose methotrexate in rheumatoid arthritisare we entering a new era of therapeutic drug monitoring and pharmacogenomics?","volume":"60","author":"Stamp","year":"2006","journal-title":"Biomed Pharmacother"},{"key":"R9-27-20210210","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000111031","article-title":"Drug safety in Crohns disease therapy.","volume":"76","author":"Juillerta","year":"2007","journal-title":"Digestion"},{"key":"R10-27-20210210","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2133.1980.tb06553.x","article-title":"Methotrexate induced liver cirrhosis; studies including serial liver biopsies during continued treatment.","volume":"102","author":"Zachariae","year":"1980","journal-title":"Br J Dermatol"},{"key":"R11-27-20210210","first-page":"459","article-title":"Toxicity of methotrexate treatment in psoriasis and psoriatic arthiritisshort- and long-term toxicity in 104 patients.","volume":"23","author":"Wollina","year":"1996","journal-title":"Clin Rheumatol"},{"key":"R12-27-20210210","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/art.1780310501","article-title":"A long-term prospective study of the use of methotrexate in rheumatoid arthritis.","volume":"31","author":"Kremer","year":"1988","journal-title":"Arthritis Rheum"},{"key":"R13-27-20210210","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0190-9622(98)70508-0","article-title":"Roenigk, Jr, HH, Auerbach R, Maibach; et al. Methotrexate in psoriasis: consensus conference.","volume":"38","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"R14-27-20210210","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.1780370304","article-title":"Methotrexate for rheumatoid arthirits. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology.","volume":"37","author":"Kremer","year":"1994","journal-title":"Arthritis Rheum"},{"key":"R15-27-20210210","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/00000478-199512000-00007","article-title":"Chronic hepatitis: an update on terminology and reporting.","volume":"19","author":"Batts","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"R16-27-20210210","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0190-9622(98)70508-0","article-title":"Methotrexate guidelines: revised.","volume":"38","author":"Roenigk","year":"1982","journal-title":"J Am Acad Dermatol"},{"key":"R17-27-20210210","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohns disease.","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med"},{"key":"R18-27-20210210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2036.2001.00908.x","article-title":"Efficacy of parenteral methotrexate in refractory Crohns disease.","volume":"15","author":"Chong","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"R19-27-20210210","first-page":"1730","article-title":"Methotrexate in Crohns disease: long-term efficacy and toxicity.","volume":"95","author":"Lemann","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R20-27-20210210","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1111\/j.1572-0241.2000.03287.x","article-title":"Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease.","volume":"95","author":"Te","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R21-27-20210210","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.0953-0673.1996.00309.x","article-title":"Methotrexate for treatment of refractory Crohns disease.","volume":"10","author":"Lemann","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"R22-27-20210210","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MCG.0b013e31802e6875","article-title":"Long-term methotrexate for Crohns disease: safety and efficacy in clinical practice.","volume":"42","author":"Domenech","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"R23-27-20210210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00054725-199902000-00002","article-title":"Methotrexate in refractory Crohns disease.","volume":"5","author":"Vandeputte","year":"1999","journal-title":"Inflamm Bowel Dis"},{"key":"R24-27-20210210","first-page":"1727","article-title":"Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis.","volume":"31","author":"Kent","year":"2004","journal-title":"J Rheumatol"},{"key":"R25-27-20210210","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1046\/j.1365-2036.2002.01227.x","article-title":"The efficacy of methotrexate for maintaining remission in inflammatory bowel disease.","volume":"16","author":"Fraser","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R26-27-20210210","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1590-8658(03)00372-4","article-title":"Comparison between methotrexate and azathioprine in the treatment of chronic active Crohns disease: a randomized, investigator-blind study.","volume":"35","author":"Ardizzone","year":"2003","journal-title":"Digest Liver Dis"},{"key":"R27-27-20210210","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF00290521","article-title":"Long-term tolerability of methotrexate at doses exceeding 15mg per week in rheumatoid arthritis.","volume":"15","author":"Schnabel","year":"1996","journal-title":"Rheumatol Int"},{"key":"R28-27-20210210","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.","volume":"58","author":"Braun","year":"2008","journal-title":"Arth Rheum"},{"key":"R29-27-20210210","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2133.1994.tb02901.x","article-title":"RJ, Kuijpers AL, Mulder J et al. Methotrexate revisited: effects of long-term treatment in psoriasis.","volume":"130","year":"1994","journal-title":"Br J Dermatol"},{"key":"R30-27-20210210","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2340\/0001555572361364","article-title":"Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy.","volume":"72","author":"Themido","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"R31-27-20210210","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2133.1980.tb06553.x","article-title":"Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment.","volume":"102","author":"Zachariae","year":"1980","journal-title":"Br J Dermatol"},{"key":"R32-27-20210210","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0002-9343(88)80019-6","article-title":"Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis: 84-month update.","volume":"85","author":"Shergy","year":"1988","journal-title":"Am J Med"},{"key":"R33-27-20210210","first-page":"489","article-title":"Methotrexate and the liver.","volume":"16","author":"Tolman","year":"1989","journal-title":"J Rheumatol"},{"key":"R34-27-20210210","first-page":"229","article-title":"Clinical liver disease in patients with rheumatoid arthritis taking methotrexate.","volume":"19","author":"Phillips","year":"1992","journal-title":"J Rheumatol"},{"key":"R35-27-20210210","first-page":"253","article-title":"Liver biopsies from psoriatics related to methotrexate therapy. Findings in 123 consecutive non-methotrexate-treated patients.","volume":"84","author":"Nyfors","year":"1976","journal-title":"Acta Pathol Microbiol Scand"},{"key":"R36-27-20210210","first-page":"A221","article-title":"Does chronic methotrexate cause liver toxicity when used for refractory inflammatory bowel disease?","volume":"100","author":"Kozarek","year":"1991","journal-title":"Gastroenterology"},{"key":"R37-27-20210210","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2036.2004.01819.x","article-title":"Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?","volume":"19","author":"Aithal","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R38-27-20210210","first-page":"1905","article-title":"Comparison of methods for identifying early methotrexate-induced hepatotoxicity in patients with rheumatoid arthritis.","volume":"34","author":"Arias","year":"1993","journal-title":"J Nucl Med"},{"key":"R39-27-20210210","first-page":"1337","article-title":"Methotrexate-induced chronic liver injury: guidelines for detection and prevention.","volume":"88","author":"Lewis Ml, Schiff","year":"1988","journal-title":"Am J Gastroenterol"},{"key":"R40-27-20210210","first-page":"459","article-title":"Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis.","volume":"23","author":"Kremer","year":"1996","journal-title":"J Rheumatol"},{"key":"R41-27-20210210","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0002-9343(91)90667-M","article-title":"Methotrexate and histologic hepatic abnormalities: a meta-analysis.","volume":"90","author":"Whiting-OKeefe","year":"1991","journal-title":"Am J Med"},{"key":"R42-27-20210210","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF00246875","article-title":"A prospective analysis of liver biopsies in rheumatoid arthritis patients receiving long-term methotrexate therapy.","volume":"12","author":"Tishler","year":"1992","journal-title":"Rheumatol Int"},{"key":"R43-27-20210210","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/art.1780350202","article-title":"Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis.","volume":"35","author":"Weinblatt","year":"1992","journal-title":"Arthritis Rheum"},{"key":"R44-27-20210210","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.gtc.2004.03.001","article-title":"Methotrexate in inflammatory bowel disease.","volume":"33","author":"Feagan","year":"2004","journal-title":"Gastroenterol Clin North Am"},{"key":"R45-27-20210210","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1572-0241.2006.00947.x","article-title":"Abnormal hepatic biochemistries in patients with inflammatory bowel disease.","volume":"102","author":"Mendes","year":"2007","journal-title":"Am J Gastroenterol"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg201021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg201021","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg201021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201007000-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:47:07Z","timestamp":1786542427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201007000-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2010.21","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.7901959.8258058","asserted-by":"object"}]},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}